Abstract
Prostacyclin (PGI2) inhibits platelet aggregation and vasoconstriction. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. Vane et al. first discovered PGI2 in 1976, for which they received the Nobel Prize in medicine and physiology in 1982. However, the later discovery of nitric oxide (NO), which also resulted in a Nobel Prize for the scientists involved, led to less attention being focused on PGI2. The reason for this is somewhat perplexing and may have been due to the lack of information on how to correctly use PGI2. Current findings suggest that researchers concentrated too much effort on the therapeutic effects of PGI2, while largely ignoring the potential for preventative effects. In addition, PGI2 was shown to be effective against diseases in some studies but was without effect in others. The present paper contains a review of PGI2 and PGIS, in addition to an examination of the relationship between PGIS gene mutations and cardiovascular diseases. PGI2 analogues that can be used in the prevention of cardiovascular diseases are also discussed.
Keywords: Prostacyclin, association study, prevention, cardiovascular diseases, mutation, polymorphism
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Volume: 4 Issue: 4
Author(s): Tomohiro Nakayama
Affiliation:
Keywords: Prostacyclin, association study, prevention, cardiovascular diseases, mutation, polymorphism
Abstract: Prostacyclin (PGI2) inhibits platelet aggregation and vasoconstriction. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. Vane et al. first discovered PGI2 in 1976, for which they received the Nobel Prize in medicine and physiology in 1982. However, the later discovery of nitric oxide (NO), which also resulted in a Nobel Prize for the scientists involved, led to less attention being focused on PGI2. The reason for this is somewhat perplexing and may have been due to the lack of information on how to correctly use PGI2. Current findings suggest that researchers concentrated too much effort on the therapeutic effects of PGI2, while largely ignoring the potential for preventative effects. In addition, PGI2 was shown to be effective against diseases in some studies but was without effect in others. The present paper contains a review of PGI2 and PGIS, in addition to an examination of the relationship between PGIS gene mutations and cardiovascular diseases. PGI2 analogues that can be used in the prevention of cardiovascular diseases are also discussed.
Export Options
About this article
Cite this article as:
Nakayama Tomohiro, Prostacyclin Analogues: Prevention of Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2006; 4 (4) . https://dx.doi.org/10.2174/187152506784111463
DOI https://dx.doi.org/10.2174/187152506784111463 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutrigenomics: Advances, Opportunities and Challenges in Understanding the Nutrient-Gene Interactions
Current Nutrition & Food Science Pulmonary Valve Endocarditis: A Case Report
Infectious Disorders - Drug Targets Bioresorbable Vascular Scaffold: Our Initial Experience
Applied Clinical Research, Clinical Trials and Regulatory Affairs Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Synthesis, Characterization and Evaluation of Gemfibrozil-Stilbene Hybrid as Antioxidant Agent
Letters in Drug Design & Discovery The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides
Protein & Peptide Letters Drug Interactions During Periodontal Therapy in HIV-Infected Subjects
Mini-Reviews in Medicinal Chemistry Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
Current Pharmaceutical Design SAR and QSAR of the Antioxidant Activity of Flavonoids
Current Medicinal Chemistry Cardiac Stem Cell Characteristics in Physiological and Pathological Conditions
Current Pharmaceutical Design Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures
Current Drug Targets Lipids and Endothelial Dysfunction
Vascular Disease Prevention (Discontinued) Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor α(PPARα) Agonists,PPARγ Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (HMG-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (ACE)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells
Current Drug Targets - Cardiovascular & Hematological Disorders